Day 3 — Wednesday Jan 14, 2026¶

Day 3 unfolded as the conference's "final full day" with no megadeal materializing despite morning anticipation among bankers; instead the day skewed toward strategic narratives — AbbVie's post-Humira runway, Sanofi navigating U.S. vaccine policy turmoil, Novo Nordisk telegraphing M&A appetite under a new CEO, and a parade of mid-cap and rare-disease names making their case. Dominant Day 3 threads: policy/politics, China innovation pace, obesity-pipeline jockeying, and rare disease as a pivotal-year story.

Cross-day note: The widely-cited Boston Scientific / Penumbra $14.5B acquisition was announced Thursday Jan 15 (Day 4), not Day 3. See Day 4.

1. AbbVie — "clear line of sight" to growth into the 2030s¶

CFO Scott Reents in a Wednesday fireside chat said AbbVie has a "clear line of sight" extending into the 2030s, citing 8% 2025 revenue growth and 19% growth in its growth platform.
Issued 2027 guidance of $31B combined for Skyrizi (~$20B) and Rinvoq (~$11B), now three years past the Humira LOE cliff.
Came on the heels of AbbVie's Day-1 $5.6B RemeGen licensing deal (RC148, PD-1/VEGF bispecific); Day 3 framing emphasized organic engine, not M&A.

Why it matters: Re-anchors the post-Humira AbbVie story as durable rather than transitional.

Source: Fierce Pharma.

2. Sanofi — vaccine policy and RSV probe dominate the Wednesday press event¶

R&D chief Houman Ashrafian and CEO Paul Hudson addressed renewed U.S. scrutiny of immunizations following CDC's narrowed childhood RSV recommendation, which directly touches Beyfortus.
Sanofi flagged a recent surprise FDA rejection (last week before JPM) as an outstanding hurdle entering 2026.
Hudson also discussed the company's late-2025 "most favored nation" pricing arrangement with the White House, which has temporarily skirted U.S. import-tariff threats.

Why it matters: Vaccines remain a policy-risk asset class for Merck, Pfizer, GSK, and Sanofi heading into 2026.

Sources: Fierce Biotech; Endpoints.

3. Novo Nordisk — M&A "with intention" under new CEO¶

Novo's BD team logged ~200 meetings during JPM week; CEO Mike Doustdar laid out 2026 priorities: rolling out semaglutide 7.2 mg, launching oral Wegovy, expanding U.S. cash-pay channels, and improving supply.
Novo signaled appetite for novel obesity/diabetes mechanisms, tolerability/dosing improvements, rare blood diseases, and obesity-complication adjacencies.
STAT framed Day 3 as the day Novo "has an eye on M&A" after losing the Metsera bidding war to Pfizer.

Why it matters: Confirms Novo is a structural buyer in the obesity ecosystem despite ceding the lead position to Lilly.

Sources: STAT; BioSpace.

4. Amgen — MariTide Phase 2 (mid-week reprise)¶

Amgen reiterated Phase 2 MariTide data: up to 20% mean weight loss in obesity-only patients and up to 17% in obesity + T2D.
T2D arm: clinically meaningful HbA1c and body-weight reduction at 24 weeks on once-monthly dosing.
Six global Phase 3 studies ongoing; a Phase 3 in T2D being prepared; safety profile consistent with GLP-1RA class.

Why it matters: Positions MariTide as a potential first once-monthly T2D therapy and Amgen's anchor in the obesity contest.

Coverage is bundled across mid-week; exact session day not pinned to Wednesday.

Source: Clinical Trials Arena.

5. Regeneron — defends Dupixent strategy, M&A discipline¶

CEO Leonard Schleifer defended Dupixent's role: now approved in 8 type-2 inflammation indications with annualized global net sales >$19B (Q4 run-rate).
Plans $6B 2026 R&D spend; flagged 2031 as the Dupixent LOE horizon.
Said large M&A often results in "value destruction" and that acquirers "in most cases, dramatically overpay."

Why it matters: Regeneron stakes out a discipline posture as peers chase deals through patent cliffs.

Sources: Endpoints; Pharmaceutical Technology.

6. Gilead — broadening virology beyond HIV/HCV¶

CMO Dietmar Berger detailed plans to extend Gilead's antiviral footprint to respiratory viruses and pandemic-potential pathogens at a JPM-adjacent event.
Builds on lenacapavir momentum; separate Fierce coverage that week framed Gilead as eyeing deals from a "position of strength."

Why it matters: Signals Gilead's intent to convert HIV cash flows into a broader infectious-disease franchise.

Source: Fierce Biotech.

7. Legend Biotech — operating profit guide for 2026, Carvykti scale-up¶

Updated JPM presentation guides to company-wide operating profit in 2026; Carvykti franchise hit operating profit in Q3 2025.
10,000+ patients treated globally; Raritan facility expansion targets up to 10,000 patients/year capacity; 279+ sites across 14 markets.
~$1B cash and time deposits as of Sep 30, 2025.

Why it matters: Cell-therapy economics inflecting toward profitability in commercial CAR-T (with J&J).

Sources: Legend Biotech IR; TipRanks.

8. Pfizer / BioNTech — COVID 2025-2026 formula immunogenicity readout¶

Phase 3 cohort of LP.8.1-adapted monovalent COVID-19 vaccine met immunogenicity endpoints in adults 65+ and 18–64 with risk conditions; ≥4-fold rise in LP.8.1-neutralizing titers at 14 days.

Why it matters: Supports continued strain-updated COVID franchise amid a more skeptical U.S. policy backdrop.

Source: Pfizer press release.

Smaller items / notable mentions¶

Biotech CEO Sisterhood second-annual Wednesday meetup drew "hundreds" — attendance roughly doubled from 2025.
Novartis CMO Shreeram Aradhye on China speed: cautioned against simple speed comparisons, citing different ecosystem, trial-enrollment economics, and payer structure.
IPO market chatter: as many as ~20 biotech IPOs could price in 2026 if windows hold (BioPharma Dive).
Rare-disease Wednesday spotlight: Rocket Pharma CEO Gaurav Shah called 2026 a "year of execution"; REGENXBIO CEO Curran Simpson framed it as "really pivotal" pending Hunter syndrome (MPS II) approval; Agios highlighted PK-activator franchise growth.
Evaluate Day 3 readout: notable presenters included AbbVie, UCB, Arcus, Disc Medicine, Immunome, Legend, 4DMT, Agios, Anavex, Neurogene, Tango.
Lonza added contracts at the Vacaville, CA biologics site it bought from Roche for $1.2B in 2024.
No Wednesday megadeal materialized; one attendee told Fierce some companies appear to be holding announcements for the TD Cowen Health Care Conference in March.

Themes dominant on Day 3¶

Policy and politics threading through pharma narratives — Sanofi's vaccine/tariff overhang, Pfizer/BioNTech's COVID franchise reframe, Moderna's break-even-by-2028 path.
Obesity competition shifts from drug-data tournament to commercial/distribution warfare (Novo's DTP/oral-Wegovy push, Amgen's once-monthly differentiation, Pfizer-Metsera looming).
Rare disease and cell/gene therapy as the "year of execution" story, aided by FDA's late-2025 plausible-mechanism pathway.
Capital-discipline rhetoric (Regeneron) coexisting with active BD pipelines (Novo, Gilead) — few megadeals on Wednesday but strong tone of asset-centric, mid-size dealmaking.

Sources¶

See Themes & takeaways for cross-day synthesis.